Safety and Effectiveness of Apixaban Versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation Stratified by Renal Function: A Retrospective Cohort Study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Safety and Effectiveness of Apixaban Versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation Stratified by Renal Function: A Retrospective Cohort Study ; volume:23 ; number:6 ; day:17 ; month:10 ; year:2023 ; pages:721-733 ; date:11.2023
American journal of cardiovascular drugs ; 23, Heft 6 (17.10.2023), 721-733, 11.2023
- Creator
-
Morimoto, Takeshi
Hoshino, Haruhiko
Matsuo, Yukako
Ibuki, Tatsuki
Miyata, Kayoko
Koretsune, Yukihiro
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40256-023-00611-7
- URN
-
urn:nbn:de:101:1-2024012213273913587804
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Morimoto, Takeshi
- Hoshino, Haruhiko
- Matsuo, Yukako
- Ibuki, Tatsuki
- Miyata, Kayoko
- Koretsune, Yukihiro
- SpringerLink (Online service)
Other Objects (12)
International Normalized Ratio Stability in Warfarin-Experienced Patients with Nonvalvular Atrial Fibrillation
Relationship of Warfarin and Apixaban with Vascular Function in Patients with Atrial Fibrillation
Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice : A propensity-matched analysis of 76,940 patients
Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study
Evaluation of Apixaban standard dosing in underweight patients with non-valvular atrial fibrillation: a retrospective cohort study
Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry
Dabigatran and warfarin in nonvalvular atrial fibrillation or atrial flutter in outpatient clinic practice in Brazil
Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation
Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation
International Normalized Ratio Stability in Warfarin-Experienced Patients with Nonvalvular Atrial Fibrillation
Relationship of Warfarin and Apixaban with Vascular Function in Patients with Atrial Fibrillation
Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice : A propensity-matched analysis of 76,940 patients
Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study
Evaluation of Apixaban standard dosing in underweight patients with non-valvular atrial fibrillation: a retrospective cohort study
Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry
Dabigatran and warfarin in nonvalvular atrial fibrillation or atrial flutter in outpatient clinic practice in Brazil
Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation
Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation
International Normalized Ratio Stability in Warfarin-Experienced Patients with Nonvalvular Atrial Fibrillation
Relationship of Warfarin and Apixaban with Vascular Function in Patients with Atrial Fibrillation
Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice : A propensity-matched analysis of 76,940 patients
Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study
Evaluation of Apixaban standard dosing in underweight patients with non-valvular atrial fibrillation: a retrospective cohort study
Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry
Dabigatran and warfarin in nonvalvular atrial fibrillation or atrial flutter in outpatient clinic practice in Brazil
Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation
Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users